Afexa Life Sciences Inc. is a health sciences and technology company, founded in 1992 and headquartered in Edmonton, Alberta, Canada. The company has developed, commercialized, and patented a proprietary technology, known as ChemBioPrint®, which is used to discover and biologically standardize natural products that deliver consistent, verifiable and provable health benefits. In 2003, Afexa Life Sciences shifted from research and development to product commercialization. Using the ChemBioPrint technology, the company's scientists are able to precisely identify the chemical profile and biological activity of natural products. The process involves a combination of chemical and pharmacological fingerprinting ensuring the creation and scientific substantiation of its natural health products are safe, effective and consistent.

Afexa Life Sciences is committed to using a pharmaceutical model with rigorous drug discovery and testing methods to develop natural therapeutics for health maintenance and disease prevention. Its efforts in scientific research and product innovation are key factors enabling the company to secure the trust of consumers, trade professionals, healthcare practitioners and government.

Afexa Life Sciences' lead product, COLD-FX®, is designed to prevent and treat colds and flu by strengthening the immune system. A U.S. FDA regulated Phase II Clinical Trial showed COLD-FX reduces the risk of getting a cold or flu by 89%. All company products are designed to support the body’s normal physiological functions with a user-friendly, natural compound. Utilizing its patented ChemBioPrint technology, Afexa Life Sciences has developed and commercialized a selection of premium quality natural health products for health maintenance and disease prevention.